Genomic Data
Solutions for Pharma
Solutions for Pharma
Empowering Pharma R&D with Rare Disease Genomic Intelligence
Are you making multimillion-dollar decisions based
on incomplete genomic data?
on incomplete genomic data?
Open-access resources like Google Scholar, ClinVar, and PubMed can miss evidence for up to 70% of clinically significant variants
In precision medicine, commonly used methods of gathering data fall short. If you are relying on data from incomplete resources, you are missing critical genomic data that can impact your entire program.
Incomplete genomic data puts drug programs at risk
The Wrong Variants
Incomplete disease understanding and enrolling patients with the wrong genomic biomarkers dilutes trial results
Inaccurate Market Analysis
Missing disease-causing variants underestimates prevalence, impairing investment, trial design, and pricing
Insufficient Diagnostic Data
Public databases don’t provide aggregate insights into diagnostic yield from genomic testing methods, labs, and the literature
Comprehensive genomic data de-risks drug programs
Genomenon combines AI and human expertise to deliver a comprehensive view of the genetics of your disease of interest, from discovery to commercialization
Understand Disease Mechanisms
Uncover pathogenic variants and relevant biomarkers to fully investigate genetic drivers of disease
Survey the Patient Universe
Review all published patient data annotated with demographic, genotype, phenotype, and CDx information
Validate Disease Prevalence
Estimate market potential with precise genetic evidence and up-to-date population databases
Increase Diagnostic Yield
Drive disease, trial & treatment awareness through our global network of clinical diagnostic labs
Get a comprehensive picture of your disease of interest
Genomic intelligence in action
Curation of the Entire Human Genome Requires the Best of Both Human and Artificial Intelligence (3:42 read)
Estimation of ENPP1 deficiency genetic prevalence using a comprehensive literature review and population databases (14:00 read)
Locus-Specific Patient Databases for Rare Disease: Patient Landscapes as Natural History Studies with Inozyme Pharma (56:00 watch)